Abemaciclib-fulvestrant improves OS in HR+, HER2- breast cancer
14 Oct 2019
bởiRoshini Claire Anthony
A combination of the CDK 4/6 inhibitor abemaciclib with fulvestrant improved overall survival (OS) in patients with HR+, HER2- advanced breast cancer (ABC), with a trend toward improved outcomes in patients with poor prognosis, according to results of the phase III MONARCH 2* trial presented at ESMO 2019.